Safety and tolerability profile of Sutent

SUTENT® AEs are well-characterised, so they can be anticipated and managed early in treatment.1–7

AEs (≥20% in any group)3

Adapted from Motzer RJ, et al. 2009 and Sutent Summary of Product Characteristics

References:

  1. SUTENT® Summary of Product Characteristics. 
  2. Negrier S. Oncology 2012;82:189–196.
  3. Castellano D, et al. Cancer Treat Rev 2013;39:230–240.
  4. Motzer RJ, et al. J Clin Oncol 2009;27:3584–3590.
  5. Ravaud A. Ann Oncol 2009;20(Suppl 1):i7–i12.
  6. Négrier S & Ravaud A. Eur J Cancer Suppl 2007;5:12–19.
  7. Hutson TE, et al. Oncologist 2008;13:1084–1096.

PP-SUT-IRL-0137  September 2020